ME02474B - Terapijski režimi - Google Patents

Terapijski režimi

Info

Publication number
ME02474B
ME02474B MEP-2016-149A MEP14916A ME02474B ME 02474 B ME02474 B ME 02474B ME P14916 A MEP14916 A ME P14916A ME 02474 B ME02474 B ME 02474B
Authority
ME
Montenegro
Prior art keywords
dosage form
unit dosage
use according
compound
oral administration
Prior art date
Application number
MEP-2016-149A
Other languages
German (de)
English (en)
French (fr)
Inventor
Louis O'dea
C Richard Lyttle
Jonathan Guerriero
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of ME02474B publication Critical patent/ME02474B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1.Jedinični dozni oblik koji obuhvata od 0,9 do 1,1 mg, od 2,2 do 2,8 mg, od 4,4 do 5,6 mg ili od 9 do 11mg jedinjenja formule I kao njegove dihidrohloridne soli za upotrebu u postupku tretiranja vazomotornih poremećaja u predmenopauznom ili postmenopauznom stanju žene kojoj je to potrebno, pri čemu postupak obuhvata davanje pacijentu jedanput dnevno pomenutog jediničnog doznog oblika.
2.Upotreba jedinjenja formule I kao njegove dihidrohloridne soli u proizvodnji leka za tretiranje vazomotornih poremećaja u predmenopauznom ili postmenopauznom stanju žene kojoj je to potrebno, pri čemu je lek jedinični dozni oblik koji obuhvata od 0,9 do 1,1 mg, od 2,2 do 2,8 mg, od 4,4 do 5,6 mg ili od 9 do 11 mg pomenutog jedinjenja, i gde postupak obuhvata davanje pacijentu jedanput dnevno pomenutog jediničnog doznog oblika.
3.Jedinični dozni oblik za upotrebu prema zahtevu 1, ili upotreba prema zahtevu 2, pri čemu jedinični dozni oblik obuhvata 1, 2,5 , 5 ili 10 mg jedinjenja formule I kao njegove dihidrohloridne soli.
4.Jedinični dozni oblik za upotrebu prema zahtevu 1, ili upotreba prema zahtevu 2, pri čemu jedinični dozni oblik obuhvata 10 mg jedinjenja formule I kao njegove dihidrohloridne soli.
5.Jedinični dozni oblik za upotrebu ili upotreba prema zahtevima 1 do 4, koji dalje obuhvata jedan ili više farmaceutski prihvatljivih ekscipijenata.
6.Jedinični dozni oblik prema zahtevu 5, pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu.
7.Jedinični dozni oblik prema zahtevu 6, pri čemu se nakon oralne primene jediničnog doznog oblika više od 50% rastvara u želucu pre nego što se oslobodi u tankim crevima.
8.Jedinični dozni oblik prema zahtevu 7, pri čemu jedinični dozni oblik nije obložen oblogom otpornom na kiseline.
9.Jedinični dozni oblik za upotrebu ili upotreba prema bilo kom od zahteva 1 do 4, pri čemu se jedinični dozni oblik primenjuje oralno, jedanput dnevno; i opciono pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu.
10.Jedinični dozni oblik za upotrebu ili upotreba prema zahtevu 9, pri čemu je jedinični dozni oblik tableta ili kapsula pogodna za oralnu primenu, a koja se više od 50% rastvara u želucu pre nego što se oslobodi u tankim crevima, a opciono pri čemu jedinični dozni oblik nije obložen oblogom otpornom na kiseline.
MEP-2016-149A 2010-05-12 2011-05-12 Terapijski režimi ME02474B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33409510P 2010-05-12 2010-05-12
EP11781299.0A EP2568806B1 (en) 2010-05-12 2011-05-12 Therapeutic regimens
PCT/US2011/036311 WO2011143469A1 (en) 2010-05-12 2011-05-12 Therapeutic regimens

Publications (1)

Publication Number Publication Date
ME02474B true ME02474B (me) 2017-02-20

Family

ID=44914714

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-149A ME02474B (me) 2010-05-12 2011-05-12 Terapijski režimi

Country Status (17)

Country Link
US (2) US20130053448A1 (me)
EP (2) EP2568806B1 (me)
CA (1) CA2799183A1 (me)
CY (1) CY1117893T1 (me)
DK (1) DK2568806T3 (me)
ES (1) ES2585884T3 (me)
HR (1) HRP20160929T1 (me)
HU (1) HUE030072T2 (me)
LT (1) LT2568806T (me)
ME (1) ME02474B (me)
MX (1) MX342898B (me)
PL (1) PL2568806T3 (me)
PT (1) PT2568806T (me)
RS (1) RS54993B1 (me)
SI (1) SI2568806T1 (me)
SM (1) SMT201600263B (me)
WO (1) WO2011143469A1 (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002490A2 (en) * 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
KR20260032534A (ko) * 2023-06-05 2026-03-09 베를린-케미 악티엔 게젤샤프트 고체 엘라세스트란트 디히드로클로라이드 조성물, 그의 제조 방법, 및 그를 사용한 치료 방법

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
JPH01261381A (ja) 1988-04-12 1989-10-18 Nippon Soda Co Ltd オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
PT918774E (pt) 1996-06-27 2002-05-31 Ligand Pharm Inc Compostos moduladores do receptor para androgenio e metodos
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
IL150463A0 (en) 1999-12-30 2002-12-01 Signal Pharm Inc Compounds and methods for modulation of estrogen receptors
BR0108107A (pt) 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
MXPA02012605A (es) 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
DE60137728D1 (de) 2000-08-24 2009-04-02 Univ Tennessee Res Foundation Selektive Modulatoren des Androgenrezeptors und Methoden zu deren Verwendung
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
NZ525551A (en) 2000-10-26 2005-09-30 Alza Corp Transdermal drug delivery devices having coated microprotrusions
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US6933321B2 (en) 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
DK1501819T3 (da) 2002-04-24 2011-01-10 Merck Sharp & Dohme Østrogenreceptormodulatorer
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
AU2003248052A1 (en) 2002-07-12 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperadine derivative
PL375042A1 (en) 2002-08-12 2005-11-14 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
US7622592B2 (en) 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
WO2004110978A2 (en) 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
KR20060038407A (ko) 2003-06-30 2006-05-03 알자 코포레이션 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
US7446110B2 (en) 2003-09-10 2008-11-04 Merck & Co., Inc. 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
ES2377647T3 (es) 2003-10-31 2012-03-29 Alza Corporation Aplicador auto-actuado para ordenamiento de microproyecciones
KR20070010115A (ko) 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1687274A1 (en) 2003-11-20 2006-08-09 Warner-Lambert Company LLC Androgen receptor modulators
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
RU2397176C2 (ru) 2004-01-07 2010-08-20 Эндорешерш, Инк. Стероидные фармацевтические продукты, направленные на спираль 12
KR100849559B1 (ko) 2004-01-22 2008-07-31 일라이 릴리 앤드 캄파니 혈관운동 증상의 치료를 위한 선택적 에스트로겐 수용체조절제
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7514470B2 (en) 2004-03-03 2009-04-07 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
CA2562132A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
JP5070042B2 (ja) 2004-05-03 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物
MXPA06013115A (es) 2004-05-11 2007-02-28 Pfizer Prod Inc Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica.
US7556821B2 (en) 2004-05-13 2009-07-07 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
EP1756101A2 (en) 2004-05-17 2007-02-28 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
EP1758874A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Substituted thiazoleacetic acids as crth2 ligands
PL1753417T3 (pl) 2004-06-07 2012-09-28 Univ Tennessee Res Found Selektywny modulator receptora androgenowego i jego zastosowania medyczne
CA2579514A1 (en) 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
EP1805147B1 (en) 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
EP1809275A1 (en) 2004-10-13 2007-07-25 Smithkline Beecham Corporation Chemical compounds
JP2008518968A (ja) 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
WO2006055184A2 (en) 2004-11-16 2006-05-26 Janssen Pharmaceutica N.V. Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
CA2587780A1 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
CN101119993B (zh) 2005-01-10 2015-03-04 阿卡蒂亚药品公司 作为选择性雄激素受体调节剂的氨基苯基衍生物
JP2008536868A (ja) 2005-04-15 2008-09-11 スミスクライン・ビーチャム・コーポレイション シアノアリールアミン
PL1891038T3 (pl) 2005-05-13 2009-04-30 Lilly Co Eli Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CA2612723A1 (en) 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators
AR057656A1 (es) 2005-07-01 2007-12-12 Ligand Pharm Inc Compuestos moduladores de receptores de androgeno y metodods relacionados
JP5070054B2 (ja) 2005-08-01 2012-11-07 武田薬品工業株式会社 環状アミン化合物
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
CA2629193C (en) 2005-11-18 2016-03-29 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
US8632801B2 (en) 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
EP1984343B1 (en) 2006-01-24 2013-02-27 Janssen Pharmaceutica N.V. 2-substituted benzimidazoles as selective androgen receptor modulators (sarms)
AU2007220419B2 (en) 2006-03-03 2012-03-15 Orion Corporation Selective androgen receptor modulators
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
BRPI0713198A2 (pt) 2006-07-19 2012-10-16 Osurf Ohio State University Res Foundation modulares seletivos de receptores de androgênio, seus análogos e derivados, e seus usos
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
JP5275236B2 (ja) 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
ES2817249T3 (es) 2007-04-16 2021-04-06 Corium Inc Matrices de microagujas obtenidas mediante disolución y colada que contienen un principio activo
ME01579B (me) 2007-08-07 2014-09-20 Takeda Pharmaceuticals Co Derivati pirolidin-2-ona kao modulatori androgenskih receptora
WO2009054988A1 (en) 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
EP2277124B1 (en) 2007-11-21 2016-11-09 Medizinische Hochschule Hannover Means for treating myosin-related diseases
CA2709514A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
CA2716320C (en) 2008-02-22 2014-01-28 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
EA019713B1 (ru) 2008-05-16 2014-05-30 Эли Лилли Энд Компани ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
KR101634836B1 (ko) 2008-12-26 2016-06-29 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
EP2566501B1 (en) 2010-05-04 2019-03-13 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
EP2575845B1 (en) 2010-05-28 2017-02-15 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
EP2699252B1 (en) 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
KR102143482B1 (ko) 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
US20160022608A1 (en) 2016-01-28
MX2012013014A (es) 2013-02-27
HRP20160929T1 (hr) 2016-10-07
EP2568806B1 (en) 2016-05-11
PT2568806T (pt) 2016-08-05
WO2011143469A1 (en) 2011-11-17
ES2585884T3 (es) 2016-10-10
EP3106159A1 (en) 2016-12-21
EP2568806A4 (en) 2013-09-11
DK2568806T3 (en) 2016-08-15
EP2568806A1 (en) 2013-03-20
US20130053448A1 (en) 2013-02-28
MX342898B (es) 2016-10-18
WO2011143469A8 (en) 2012-01-19
HUE030072T2 (en) 2017-04-28
LT2568806T (lt) 2016-09-26
CA2799183A1 (en) 2011-11-17
US9555014B2 (en) 2017-01-31
RS54993B1 (sr) 2016-11-30
SMT201600263B (it) 2016-08-31
SI2568806T1 (sl) 2016-09-30
CY1117893T1 (el) 2017-05-17
PL2568806T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
ME02474B (me) Terapijski režimi
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2015038135A5 (me)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
ME02179B (me) Metoda za lečenje atrijalne fibrilacije
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2011068653A5 (me)
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
NZ714963A (en) Compositions and methods for treating anemia
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
JP2013231087A5 (me)
JP2015519329A5 (me)
JP2017506624A5 (me)
JP2015522630A5 (me)
TN2011000307A1 (en) Galenic formulation of organic compounds
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2019218379A5 (me)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
JP2016507500A5 (me)
JP2016505050A5 (me)
RU2020123405A (ru) Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
HRP20161796T1 (hr) Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice